12/18/2020 - In a collaboration with Truvitech, scientists at UC San Diego, University of California, Davis, University of Miami, Wilmer Eye Institute At Johns Hopkins, Stanford University, and University of California, San Francisco deployed Truvitech's idTRAX technology to identify the first group of kinase targets that provide long-term neuroprotection of retinal ganglion neurons while simultaneously promoting axon regeneration in those neurons. This discovery, just published in PNAS, will have significant implications for the treatment of chronic neurodegenerative diseases such as glaucoma.

10/10/2020 - Truvitech is participating in the Life Sciences Summit 2020 conference. Check out our 7 min pitch.

12/17/2019 - Truvitech will be at the JP Morgan 2020 Healthcare conference in San Fransisco. Take a look at our one pager and come talk to us about investment and partnering opportunities.

09/18/2019 - Co-founder Vance Lemmon's presentation on the latest successes of the idTRAX platform was well received by the audience at the Society for Biomolecular Imaging and Informatics (SBI2) meeting in Boston.  

08/11/2019 - Truvitech successfully validated its novel DLBCL drug target candidate using both genetic and chemical approaches in vitro. Work is being done now to validate this target in four different in vivo models of DLBCL representing ABC (naive/treated) and GCB (naive/treated) subtypes.

05/02/2019 - Breast cancer study utilizing idTRAX was published in Cell Chemical Biology


04/01/2019 - Truvitech successfully completed studies proposed in its Phase I STTR. Work is now being done to validate a novel target that was discovered for DLBCL. Small-molecules that engage this target selectively kill DLBCL tumor cells without affecting the viability of normal blood cells, making it an ideal target candidate for drug development.

03/05/2019 - Co-founder Hassan Al-Ali's presentation "Re-thinking drug target identification" was well received by the audience at the Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1) Keystone Symposium.

12/01/2018 - Truvitech completed a screening campaign with 10 DLBCL cancer lines and peripheral blood mononuclear cells and deployed idTRAX to identify a novel kinase target that selectively sensitizes DLBCL cells without affecting the viability of normal cells.

08/01/2018 - Truvitech's idTRAX approach successfully identifies anti-viral drug targets.

05/01/2018 - Santiago Vilar joins Truvitech LLC.

04/01/2018 - Truvitech initiates collaboration with the University of Miami (PI Jonathan Schatz) to identify Diffuse B-Cell Lymphoma (DLBCL)-selective drug targets.

02/08/2018 - Truvitech LLC joins CIC Miami.

02/03/2018 - Truvitech LLC receives notice that its STTR application to the NIH has been selected for funding.

02/01/2018 - Truvitech's idTRAX approach successfully identifies triple negative breast cancer-selective drug targets.

01/29/2018 - Truvitech LLC is seeking a talented postdoc to join our startup. If interested, please check the job description and apply here